A purple and pink letter v on a white background.
March 25, 2020

Boost Clinical Efficacy Using Venus Viva™

The desire for clean, clear, and youthful skin is what drives the skin rejuvenation market. As physicians and treatment providers, it is imperative to learn how not only to exist in these markets, but to also maximize treatment efficacy. This, in turn, helps to establish a loyal customer base which then contributes to business success.  

Fortunately, we have Stephen Eubanks, MD —National Director of Medical and Cosmetic Lasers Advanced Dermatology & Cosmetic Surgery. In this bulletin, he explains what it takes to maximize treatment efficacy for acne scars using fractional radio frequency with the help of a Venus Viva™. He begins with some of the most common concerns presented by patients and how to tackle these.  

According to Dr. Eubanks, the  Venus Viva™ system allows him to achieve the optimum balance between providing a complete treatment capable of  resurfacing the skin and remodeling deep acne scars while also reducing the downtime for patients. Treatments with this device are applicable to patients of all Fitzpatrick skin types with no post-inflammatory hyperpigmentation (PIH) . This helps to widen the target audience for skin resurfacing treatments.  

Procedure time combined with device parameters and modalities are pivotal factors that make Venus Viva™ unequivocally useful in providing a treatment to acne scars that is both effective and comfortable. Dr. Eubanks delves into the specifics with his preferred parameter settings giving you a clear idea of what works for his patients and practice, and a near step-by-step explanation of his procedures.  

This bulletin clearly surmises how to get the most out of your Venus Viva™ skin resurfacing device, using it to not only cater to a customer base, but to also secure one.  

Click the download button below to read Dr. Eubanks’ take on maximizing the efficacy of fractional radio frequency for treating acne scars.

July 28, 2026
TORONTO, July 28, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced it has entered into an exclusive distribution agreement with HIRONIC Co. Ltd. (“HIRONIC”), a KOSDAQ listed South Korean company specializing in medical aesthetic devices, pursuant to which the Company acquires the exclusive right to distribute HIRONIC’s Doublo 2.0 device in the United States and Canada. The “New Doublo 2.0” is a synergistic, multi-energy-based medical device platform for the face and body, equipped with two separate handpieces that enables clinics to offer customer Cold Plasma and RF microneedling treatments. The device has received 510(k) certification from the U.S. Food and Drug Administration, and the Company intends to make it available to customers in the United States during 2H 2026. Venus Concept will support future regulatory approval efforts in Canada for the device and any additional handpiece technologies for both regions. “HIRONIC is a global leader in developing innovative medical aesthetic technologies and we are excited for the new partnership, starting with the Doublo x Venus Signature Edition,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “With this device, we look forward to offering our customers an innovative, exclusive Cold Plasma and RF Microneedling platform. By combining these complementary technologies, the platform delivers synergistic effects from the epidermis to the dermis, enabling comprehensive skin rejuvenation by addressing multiple skin concerns and enhancing overall skin revitalization. The Doublo also complements our existing portfolio by enhancing the range of treatment modalities for a customizable treatment plan to address each patient’s skin needs. We aim to expand our partnership in the future to bring to our customers additional new and novel technologies from HIRONIC, once regulatory approvals have been obtained.” About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. Investor Relations Contact: Damian Yeung, CPA investorrelations@venus.ai View Full Article
May 22, 2026
Skin Cancer Awareness Month highlights prevention and early detection. Learn how dermatologists support care with advanced tools and treatments.
May 22, 2026
Skin cancer radiotherapy improves treatment precision and patient outcomes. Learn how dermatology clinics use it in modern care plans.